ProxsysRx is pleased to announce the election of Rebecca Shanahan, Tom Greer and Jeff Muir to its Board of Directors. They join George B. Salem, G. Ruffner Page, Jr. and George I Lazenby IV on the ProxsysRx board. All three new directors have extensive experience in the healthcare sector and have led successful mergers and acquisitions.
Rebecca Shanahan is an accomplished healthcare CEO with extensive experience starting, building, and growing businesses that have generated sustained stakeholder value across publicly traded, private-equity sponsored, founder-owned, and tax-exempt healthcare services companies. Her firm, Shanahan Capital Ventures, LLC, focuses on developing, scaling, and re-structuring healthcare businesses and supporting investors in the acquisition, growth, and sale of healthcare assets.
Rebecca previously served in leadership roles at Avella Specialty Pharmacy, Aetna Specialty Pharmacy, Oncology Therapeutic Network, Shopper’s Drug Mart, Cardinal Health, Priority Healthcare, University of Chicago Faculty Practice Plan & Healthcare Systems, IU Methodist Health Systems and Community Hospitals of Indiana. She is a past president and a current member of the Board of Directors of the National Association of Specialty Pharmacy.
She was recognized as a 2017 Ernst & Young Regional Healthcare Entrepreneur of the Year and was the 2018 recipient of the NASP Distinguished Service Award and 2016 NASP Specialty Pharmacy of the Year.
Tom Greer is a Founder and Partner of Fulcrum Equity Partners and has over 20 years of investment, financial and operating experience. Tom was the Founder, President and Chief Executive Officer of Regency Healthcare, Inc. (“Regency”) a provider of hospice services throughout the Southeast and as Chairman of the Board at successor firm Regency Healthcare Group until the sale of Regency to GTCR.
Prior to founding Regency, he was Vice President of Healthcare Investment Banking for Robinson Humphrey where he worked on mergers, acquisitions, private placements, and public offerings for healthcare and life science companies.
Prior to Robinson Humphrey Tom was an executive in the Corporate Finance and Investment Banking Group at Eli Lilly & Company. He worked exclusively on structuring and negotiating licensing arrangements, joint ventures, acquisitions and investments with domestic and international biotechnology and pharmaceutical companies. Prior to Eli Lilly, he served as a Director in KPMG’s Health Ventures practice.
Jeff Muir is a founder and partner of Fulcrum Equity Partners and its predecessor firm, Fulcrum Ventures. He has managed over $350 million in capital and led or participated in 150 transactions, including public offerings, multi-party mergers and consolidation plays.
Prior to forming Fulcrum, Jeff was COO of OnTarget, the leading provider of consulting and training to large sales organizations worldwide, including IBM, HP, Cisco, Dell, Microsoft, and others. He spearheaded the highly successful exit strategy for the owners, resulting in a merger with Siebel Systems in December 1999.
Prior to OnTarget, Jeff held senior executive positions with rapidly growing companies, including NYSE health care company, T2 Medical, and Information Systems of America. He was and co-founder/principal of a physician management firm that merged with PhyMatrix as part of its initial public offering. He also served as a managing director in the corporate finance practice of KPMG. He began his career as an attorney with the Atlanta law firm of Alston & Bird.
ProxsysRx is a healthcare solutions company providing value, revenue, and savings to hospital and health system partners through inpatient and outpatient engagement and comprehensive pharmacy programs. Benefits to ProxsysRx partners include readmission risk reduction, 340B savings, employee benefit cost savings, and improved patient satisfaction. ProxsysRx services for hospitals and health care systems include onsite retail pharmacy, 340B administration, personalized and digital patient engagement and management, and employee health benefit program management.